AACR Blog Turns 4: How Far Has Immunotherapy Advanced in That Time?

Posted on by Karen Honey, PhD | Leave a comment

This week marks the fourth anniversary of Cancer Research Catalyst, the official blog of the American Association for Cancer Research (AACR). As outlined in the welcome post from AACR Chief Executive Officer Margaret Foti, PhD, MD (hc), the blog was launched to increase the spread of new knowledge about cancer.

Over these four years, our blog posts have disseminated information about advances across the breadth of cancer research and the clinical cancer care continuum. One area in which advances have occurred at a particularly rapid pace is immunotherapy.

Read More

AACR Journals to Share Editors’ Picks

Posted on by Cancer Research Catalyst staff | Leave a comment

The American Association for Cancer Research (AACR) publishes eight esteemed scientific journals. Each month, these journals feature a wide range of peer-reviewed research that encompasses the entire spectrum of cancer science. Some of the world’s leading cancer scientists publish articles in our journals, contributing greatly toward the AACR’s mission to prevent and cure cancer through research, education, communication, and collaboration.

We are pleased to debut a new feature on the blog, Editors’ Picks. Each month, AACR journal editors will share a curated list of original articles, representing each publication. While our journals are subscription-based, the stories featured in Editors’ Picks will be freely available for the month.

Read More

FDA Expands Use of Pembrolizumab to Two Additional Cancer Types

Posted on by Karen Honey, PhD | Leave a comment

Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab (Keytruda) is a treatment option when it approved the immunotherapeutic for treating certain patients with cervical cancer and certain patients with non-Hodgkin lymphoma.

Read More

Q&A With Ari M. Melnick, MD, on Recent Advances in Lymphoma

Posted on by Karen Olsen, PhD | Leave a comment

Lymphomas are a collection of blood cancers stemming from aberrant lymphocytes, which are critical components of the immune system. Lymphomas are classically divided into two categories – Hodgkin lymphoma (HL), and Non-Hodgkin lymphoma (NHL). It is estimated that over 90 percent of lymphomas are NHL, of which there are many distinct subtypes. Recent statistics estimate that nearly 75,000 new cases of NHL will be diagnosed in 2018.

Read More

AACR Award Recipient Tells Her Story in NY Times

Posted on by AACR Press Office | Leave a comment

For many aspiring investigators, pursuing a career in cancer research can be a complex exploration of self and purpose.

In this touching and inspiring piece published in The New York Times, a former AACR Undergraduate Scholar Awardee, Mya Roberson, now a doctoral student at the University of North Carolina Gillings School of Global Public Health, shares how her participation in the AACR Annual Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved helped her realize the meaning in her research.

Read More

STAR Act Aims to Boost Pediatric Research

Posted on by AACR Press Office | Leave a comment

This week, President Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, which is aimed at supporting pediatric cancer research. The legislation calls for expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.

Read More

Disparities in End-of-Life Care

Posted on by Cancer Today Staff | Leave a comment

For cancer patients at the ends of their lives, hospice care can provide access to comfort measures and extra help. Medicare offers hospice benefits to eligible patients. But not all patients have equal access to this care, research indicates.

In the spring issue of Cancer Today, medical and business journalist Charlotte Huff writes about disparities in end-of-life care affecting U.S. cancer patients.

Read More